TAp63-Regulated miRNAs Suppress Cutaneous Squamous Cell Carcinoma through Inhibition of a Network of Cell-Cycle Genes
Open Access
- 10 March 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 80 (12), 2484-2497
- https://doi.org/10.1158/0008-5472.can-19-1892
Abstract
This study provides preclinical evidence for the use of miR-30c-2*/miR-497 delivery and AURKA inhibition in the treatment of cuSCC, which currently has no FDA-approved targeted therapies.Other Versions
Funding Information
- HHS | NIH | National Cancer Institute (R35CA197452)
- Cancer Prevention and Research Institute of Texas (RP170005)
- HHS | NIH | National Cancer Institute (P30CA076292)
- HHS | NIH | National Institute of Environmental Health Sciences (P30ES030285)
This publication has 51 references indexed in Scilit:
- TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusionsGenome Biology, 2013
- Comprehensive genomic characterization of squamous cell lung cancersNature, 2012
- Proliferation and Tumorigenesis of a Murine Sarcoma Cell Line in the Absence of DICER1Cancer Cell, 2012
- MicroRNAs in Stress Signaling and Human DiseaseCell, 2012
- TAp63γ enhances nucleotide excision repair through transcriptional regulation of DNA repair genesDNA Repair, 2012
- TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAsNature, 2010
- TAp63 Prevents Premature Aging by Promoting Adult Stem Cell MaintenanceCell Stem Cell, 2009
- MicroRNAs: Target Recognition and Regulatory FunctionsCell, 2009
- p63 and p73 are required for p53-dependent apoptosis in response to DNA damageNature, 2002
- Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip: Implications for treatment modality selectionJournal of the American Academy of Dermatology, 1992